

## Neuropeptide AF (cattle)

<b>Cat. No.:</b>	HY-P3843
<b>CAS No.:</b>	99588-52-0
<b>Molecular Formula:</b>	C <sub>89</sub> H <sub>130</sub> N <sub>24</sub> O <sub>24</sub>
<b>Molecular Weight:</b>	1920.13
<b>Sequence Shortening:</b>	AGEGLSSPFWSLAAPQRF-NH2
<b>Target:</b>	Mas-related G-protein-coupled Receptor (MRGPR); Neuropeptide Y Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Neuropeptide AF (cattle), an amidated octadecapeptide, is RFamide neuropeptide. Neuropeptide AF (cattle) acts as a ligand of Mas-related gene receptor A4 (MrgprA4) (Mas-related G-protein-coupled Receptor (MRGPR)) (EC <sub>50</sub> of ~60 nM) and MrgprC11 (EC <sub>50</sub> of ~300 nM). Neuropeptide AF (cattle) also activate to the G protein-coupled receptors NPFF1 (Neuropeptide Y Receptor) (EC <sub>50</sub> of ~25-325 nM) and NPFF2 (EC <sub>50</sub> of ~1-5 nM). Neuropeptide AF (cattle) shows anti-opiate and related pain modulation effects <sup>[1][2]</sup> .								
<b>In Vitro</b>	Neuropeptide AF (NPAF) (50, 100, 150, 300, and 600nM) induces a piecemeal degranulation in bone marrow-derived mucosal mast cells (BMMCs). Neuropeptide AF can be considered as a novel modulator of BMMC activity in the neuro-immune communication in the gastrointestinal tract <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
<b>In Vivo</b>	Neuropeptide AF (cattle) (0.25 µg/2 µL; i.c.v.; 30 min prior to the tests) decreases the immobility time and increases the climbing and swimming times in modified mouse forced swimming test (mFST) <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table> <tr> <td><b>Animal Model:</b></td> <td>Male CFLP mice (25-28 g)<sup>[2]</sup></td> </tr> <tr> <td><b>Dosage:</b></td> <td>0.25 µg/2 µL</td> </tr> <tr> <td><b>Administration:</b></td> <td>i.c.v.; 30 min prior to the tests</td> </tr> <tr> <td><b>Result:</b></td> <td>Decreased the immobility time and increased the climbing and swimming times.</td> </tr> </table>	<b>Animal Model:</b>	Male CFLP mice (25-28 g) <sup>[2]</sup>	<b>Dosage:</b>	0.25 µg/2 µL	<b>Administration:</b>	i.c.v.; 30 min prior to the tests	<b>Result:</b>	Decreased the immobility time and increased the climbing and swimming times.
<b>Animal Model:</b>	Male CFLP mice (25-28 g) <sup>[2]</sup>								
<b>Dosage:</b>	0.25 µg/2 µL								
<b>Administration:</b>	i.c.v.; 30 min prior to the tests								
<b>Result:</b>	Decreased the immobility time and increased the climbing and swimming times.								

### REFERENCES

[1]. Nada Abdellah, et al. Neuropeptide AF Induces Piecemeal Degranulation in Murine Mucosal Mast Cells: A New Mediator in Neuro-Immune Communication in the Intestinal Lamina Propria? *Anat Rec (Hoboken)*. 2018 Jun;301(6):1103-1114.

[2]. Miklós Palotai, et al. Neuropeptide AF induces anxiety-like and antidepressant-like behavior in mice. *Behav Brain Res*. 2014 Nov 1;274:264-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA